NEOPARP (SOLTI-0902)
Clinical Trial Program
A randomized, open-label, phase II study of the efficacy and safety of weekly paclitaxel single-agent and two different regimens of the PARP-1 inhibitor SAR240550 (BSI-201) in combination with weekly paclitaxel, as neoadjuvant therapy in patients with Stage II-IIIA triple negative breast cancer
Phase II
Status
Finished
Tumour subtype:
TNBC
Scenario
Neoadjuvant
Sites
